Oxford Nanopore Technologies (LSE: ONT) is a growth stock I’ve considered a couple of times for my Stocks and Shares ISA. One of my sticking points though has been its high valuation.
But now the share price has fallen around 51% in 2024, I’m taking another look.
Innovative tech
The company has developed the world’s only nanopore DNA and RNA sequencing platform. This involves passing genetic material through tiny holes called nanopores (hence the firm’s name).
As the substance passes through these, it produces electrical signals that are used to decipher the sequence of DNA and RNA. And this method can result in real-time data for rapid insights.
Its portable MinION device is significantly smaller than traditional sequencing machines, offering greater flexibility. Researchers can use them in remote locations, thereby expanding the firm’s total addressable market.
Strong growth
In 2023, underlying life science research tools revenue grew 39% year on year to £170m, excluding legacy Covid-related contracts. Its active customer accounts increased 11% to over 7,600.
This is important because 74% of its revenue came from consumables last year. In other words, it makes most of its money providing supplies after it has sold a device — that’s a ‘razor-and-blades’ business model.
I like this model as it can result in serious profits. However, not for Oxford Nanopore… yet. It reported a £154.5m total loss for the year (much wider than 2022’s £91m loss).
Moreover, it moved its adjusted EBITDA breakeven target from 2026 to the end of 2027. This has likely weakened investor sentiment.
Looking ahead though, management is guiding for 20%-30% underlying revenue growth this year. And greater than 30% in the medium term. Therefore, the growth story is intact here.
Comparing stocks
The performance of two of its rivals hasn’t been much better recently. Shares of Pacific Biosciences of California are down 87% in the last year, while Illumina has shed over 40% of its value.
These competitors aren’t expecting much (if any) top-line growth in 2024, which makes Oxford Nanopore’s forecast growth appear even more impressive.
Looking at the price-to-sales (P/S) ratio though, the stock is more expensive (6.19) than these US peers.
That said, the forward-looking P/S multiple for 2024 drops to 4.9, which is more attractive.
Vultures circling
Unfortunately, investors today have little patience for firms with sales but only possible future profits. They want reliable profits now, and the business isn’t about to deliver this, so there’s a risk the shares drift even lower.
In this scenario, I think the company could become an acquisition target. It has world-class technology and a growing market opportunity.
We’ve just seen UK cybersecurity firm Darktrace snapped up. So we know private equity vultures are hovering.
Should I buy some shares?
I’ve had my fingers burnt lately investing in Moderna and Ginkgo Bioworks. They’re down between 30% and 50% so far for me. So I don’t have the stomach to invest in yet another loss-making healthcare stock.
However, if this wasn’t the case, I’d consider Oxford Nanopore stock after its 51% drop. It’s seeing increasing adoption of its devices across various research areas, while the market cap is just £833m.
The shares could rebound strongly if market sentiment changes or a bidder emerges — not that I’d ever buy purely on takeover speculation.
The post Down 51% in 2024, is this UK growth stock a buy for my Stocks and Shares ISA? appeared first on The Motley Fool UK.
Like buying £1 for 31p
This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!
Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.
What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?
See the full investment case
More reading
These 3 growth stocks still look dirt cheap despite the FTSE hitting all-time highs
Here’s how much I’d need to invest in UK income stocks to retire on £25k a year
If I’d invested £5,000 in BT shares three months ago here’s what I’d have today
Here’s how I’d aim for a million, by investing £150 a week
Here’s how the NatWest dividend could earn me a £1,000 annual passive income!
Ben McPoland has positions in Ginkgo Bioworks and Moderna. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
